A bispecific IgG1 monoclonal antibody targeting EGFR and MET that blocks ligand binding, promotes receptor internalization and degradation, and mediates Fc-dependent ADCC/ADCP against EGFR/MET-expressing tumor cells.
Amivantamab is a human bispecific IgG1 monoclonal antibody targeting EGFR and MET. It blocks ligand binding and receptor phosphorylation, induces receptor internalization and degradation, and engages Fc-dependent effector functions (ADCC/ADCP) to eliminate EGFR/MET-expressing tumor cells and inhibit downstream signaling.
YES
DIRECT
Amivantamab binds EGFR on target cells and its IgG1 Fc recruits Fc receptor–bearing immune cells to mediate ADCC and ADCP, killing EGFR-expressing cells; it also promotes receptor internalization/degradation.
A bispecific IgG1 monoclonal antibody targeting EGFR and MET that blocks ligand binding, promotes receptor internalization and degradation, and mediates Fc-dependent ADCC/ADCP against EGFR/MET-expressing tumor cells.
Amivantamab is a human bispecific IgG1 monoclonal antibody targeting EGFR and MET. It blocks ligand binding and receptor phosphorylation, induces receptor internalization and degradation, and engages Fc-dependent effector functions (ADCC/ADCP) to eliminate EGFR/MET-expressing tumor cells and inhibit downstream signaling.
YES
DIRECT
Amivantamab binds MET on target cells and engages Fcγ receptor–bearing immune cells to mediate ADCC/ADCP, directly killing MET-expressing cells (with additional receptor internalization/degradation).
An anti-CD19 antibody–drug conjugate (ADC) that binds CD19 on B cells, is internalized, and releases a pyrrolobenzodiazepine (PBD) DNA-crosslinking cytotoxic payload to induce apoptosis.
An anti-CD19 antibody–drug conjugate that binds CD19 on B cells, is internalized, and releases a pyrrolobenzodiazepine (PBD) dimer payload which creates DNA interstrand crosslinks in the minor groove, inhibiting DNA replication and inducing apoptosis of CD19-expressing tumor cells.
YES
DIRECT
ADC binds CD19, is internalized, and releases a PBD dimer that creates DNA interstrand crosslinks, blocking replication and inducing apoptosis of CD19+ cells.
An anti-CD19 antibody–drug conjugate (ADC) that binds CD19 on B cells, is internalized, and releases a pyrrolobenzodiazepine (PBD) DNA-crosslinking cytotoxic payload to induce apoptosis.
An anti-CD19 antibody–drug conjugate that binds CD19 on B cells, is internalized, and releases a pyrrolobenzodiazepine (PBD) dimer payload which creates DNA interstrand crosslinks in the minor groove, inhibiting DNA replication and inducing apoptosis of CD19-expressing tumor cells.
NO
INDIRECT
The ADC binds CD19 on B cells, is internalized, and releases a PBD payload that crosslinks DNA at the N2 of guanine in the minor groove, blocking replication and inducing apoptosis in CD19-positive cells; DNA is the intracellular payload target, not the direct targeting antigen.
An intravenous recombinant bispecific IgG monoclonal antibody that targets PD-L1 and CD47. It blocks PD-L1 to release the PD-1/PD-L1 immune checkpoint and blocks CD47 to disrupt the “don’t-eat-me” signal, enhancing macrophage-mediated phagocytosis and T-cell activation. Phase 1 dose escalation (0.1–6 mg/kg weekly) in advanced solid tumors.
Bispecific IgG that binds PD-L1 and CD47. Blocks PD-L1 to release the PD-1/PD-L1 immune checkpoint and restore T‑cell activation; blocks CD47 to disrupt CD47–SIRPα “don’t‑eat‑me” signaling, promoting macrophage-mediated phagocytosis. Fc effector function can add ADCP/ADCC, enhancing anti-tumor immunity.
YES
DIRECT
IMM2520 binds PD-L1 with an IgG1 Fc, opsonizing PD-L1+ cells for Fc gamma receptor–mediated ADCC by NK cells and ADCP/phagocytosis by macrophages; simultaneous CD47 blockade removes the don’t-eat-me signal, further enhancing macrophage-mediated killing. (PD-1/PD-L1 blockade also restores CTL activity, an indirect effect.)